Evidence Standards
We define clear evidence hierarchies and readiness criteria to support disciplined, credible translation.
Translational Oncology Institute
Evidence-Led Translation for Oncology Innovation
We build standards, education, and collaborative frameworks that help early signals become credible evidence, communicated with care and aligned with patient impact.
Evidence Standards
Rigor for early signals, reproducibility, and validation.
Responsible Translation
Ethical communication grounded in patient outcomes.
Founder Education
Training for scientific entrepreneurs and clinical teams.
Institute Focus
Signal-to-evidence pathways for translational readiness.
Global Collaboration
Cross-disciplinary partners advancing patient benefit.
AionWell Foundation
Translational Rigor for Patient Impact
We advance evidence standards for early oncology translation. The institute builds methods for rigorous validation, responsible communication, and founder education to improve how scientific signals mature into patient-centered therapeutic readiness.
Guiding principle
Evidence and ethics must lead early oncology innovation — with patient impact as the measure of value.
We convene global collaborators to strengthen translational integrity, founder readiness, and responsible scientific practice.
Institute Brief
The Translation Gap in Early Oncology Innovation
Promising oncology signals are frequently delayed in translation. The gap is less about discovery and more about evidence structure, communication discipline, and patient-centered development logic.
Where signals lose momentum
- Unclear evidence hierarchy and overstated claims.
- Insufficient translational or clinical validation.
- Weak documentation discipline and traceability.
- Unresolved patient-selection logic and endpoint fit.
- Misalignment with clinical, regulatory, or BD expectations.
- Fragmented translation into patient-centered plans.
Founder Education
We build translation literacy across endpoints, patient selection, regulatory expectations, and data-room rigor.
Ecosystem Collaboration
We convene clinical and translational stakeholders to align signals with responsible patient-centered pathways.
Programs & Practice
Core Programs
AionWell Foundation convenes structured programs that reinforce evidence standards, translational readiness, and ethical communication — building the shared language required for responsible oncology innovation.
Flagship Intelligence Brief
ASCO Translational Oncology Intelligence Brief
Annual public education brief translating key conference signals into practical, evidence-grounded insights. Focused on SOC-relevant findings, evidence gaps, emerging opportunities, and responsible interpretation of early oncology data.
Evidence Standards
Early Oncology Evidence Standards Initiative
Public education program advancing responsible evaluation and communication of early oncology signals, including real-world data, compassionate use observations, imaging findings, safety reporting, and biomarker logic.
Founder Education
Translational Oncology Founder Fellowship
Selective education fellowship for early founders and translational leaders, covering evidence hierarchy, clinical signal interpretation, development readiness, patient-centered design, and ethical scientific communication.
Scientific Working Group
Molecular Imaging & Localization in Oncology Working Group
Cross-disciplinary working group advancing molecular imaging, lesion-level response evaluation, radiopharmaceutical approaches, local-to-systemic mechanisms, and probe-based oncology technologies.
Leadership Circle
Women in Translational Biotech Leadership Circle
Leadership circle supporting women in translational biotech through mentorship, board communication, negotiation practice, scientific leadership, and founder resilience.
Evidence Standard
Evidence Before Hype
Early oncology signals require disciplined interpretation. We separate observation from evidence, clarify what is known, and set responsible expectations for translation.
Focus Areas
Editorial FrameworkClinical signal interpretation
Define what the data supports and what remains preliminary.
Real-world evidence and compassionate use boundaries
Set clear guardrails for use outside controlled studies.
Imaging and lesion-level evidence
Apply rigor to radiographic and lesion response claims.
Safety and adverse event reporting
Track and disclose harm signals with clarity.
Biomarker and patient selection logic
Align selection criteria with mechanistic and clinical evidence.
Translational readiness
Assess whether the evidence warrants the next step.
Responsible claims language
Match public statements to the strength of evidence.
Research Focus
Translational rigor, anchored in patient impact.
The Institute advances evidence-first assessment of early oncology signals, translating scientific promise into disciplined clinical judgment. Our focus is on clarity, restraint, and patient-centered development.
Domains
Focused translational platforms
Molecular imaging & diagnostics
Signal validation
Immunotherapy & microenvironment
Translational readiness
mRNA/LNP delivery systems
Framework mapping
Radiopharmaceuticals
Evidence synthesis
Antibody & probe platforms
Indication strategy
Biomarker strategy
Clinical alignment
Emerging therapeutic modalities
Patient impact lens
Understated scientific abstraction
Visuals reference imaging, cellular dynamics, and molecular structure with restraint.
Who we serve
A trusted institute for evidence-first oncology translation
We support founders, scientists, and clinicians advancing early oncology signals with rigor, transparency, and global responsibility.
Oncology founders
Builders seeking evidence standards, translational readiness, and responsible claims.
Translational researchers
Scientists converting early signals into clear hypotheses and evidence pathways.
Clinician innovators
Clinicians shaping patient-centered study design and translational decisions.
Educators & mentors
Leaders advancing evidence literacy, regulatory framing, and ethical translation.
Ecosystem partners
Institutions committed to higher evidence standards and cross-disciplinary practice.
Mission-aligned collaborators
Global collaborators prioritizing patient impact, ethics, and verifiable progress.
A nonprofit platform for education, standards, and collaboration
We convene experts across regions to strengthen evidence pathways and reduce overclaiming in early oncology development.
Evidence benchmarks and translational readiness guidance.
Founder education grounded in scientific rigor.
Responsible collaboration across the global oncology ecosystem.
Ecosystem
Ecosystem Infrastructure for Translational Oncology
We convene clinicians, translational researchers, founders, imaging and biomarker specialists, regulatory and CMC leaders, and patient advocates to align evidence standards and accelerate responsible translation from signal to patient impact.
Evidence structure
Shared frameworks for validation, readiness, and claims discipline.
Cross-disciplinary collaboration
Global partners aligned on translational rigor and patient-centered development.
Translational Flow
Signal to patient-centered development
Scientific Signal
Evidence Structure
Translational Readiness
Patient-Centered Development
Founder Education
Forming Scientific Founders in Translational Oncology
We educate founders and scientific teams committed to rigorous oncology translation. The curriculum strengthens evidence standards, translational judgment, and ethical communication—clarifying what constitutes a decision-ready program versus a promising but unstructured signal.
Curriculum Focus
-
Evidence architecture
Convert early signals into decision-grade evidence packages.
-
Translational logic
Align mechanism, trial design, and patient relevance with rigor.
-
Ethical communication
Ensure claims, narratives, and disclosures reflect the evidence.
-
Partnership readiness
Prepare collaborative dossiers grounded in translational validity.
Structured, founder-respectful cadence
Small-cohort intensives, peer review, and applied guidance that reinforce disciplined scientific leadership.
COLLABORATION
Collaborate With Us.
We convene clinicians, researchers, founders, educators, and patient-centered partners committed to rigorous translational oncology standards and responsible innovation.
Public education
Open resources that strengthen evidence literacy and translational readiness.
Roundtables
Structured convenings that align cross-disciplinary evaluation.
Reports
Briefs that translate complex signals into credible guidance.
Founder fellowship
Education for scientific rigor, clarity, and responsible execution.
Working groups
Focused teams advancing shared evaluation frameworks.
Evidence standards
Co-developed guidance for quality and responsible claims.
Responsible innovation programming
Programs linking patient-centered translation with ethical, globally credible practice.
Reports & Insights
Reports & Insights Archive
A curated record of briefs, standards guides, and translational notes organized for evidentiary clarity, clinical context, and accountable communication.
Archive cadence
Quarterly public releases with controlled draft circulation for collaborating institutions. Access is governed by institute collaboration policy.
Archive access framework
Forthcoming
Institute Archive
ASCO 2026 Translational Oncology Brief
Conference brief
Release: Upcoming
Forthcoming
Institute Archive
Early Oncology Evidence Standards Guide
Standards guide
Release: Upcoming
Forthcoming
Institute Archive
Molecular Imaging in Oncology Innovation
Technical brief
Release: Upcoming
Forthcoming
Institute Archive
Responsible Communication of Early Clinical Signals
Ethics note
Release: Upcoming
Forthcoming
Institute Archive
Founder Guide to Translational Readiness
Field guide
Release: Upcoming
Governance & Ethics
Governance, Independence & Responsible Boundaries
Translational Oncology Institute is an education and research initiative. It does not provide investment advice, fundraising services, securities brokerage, commercial endorsement, or project-specific private diligence.
Boundary statement
The Institute is committed to transparency, responsible communication, and appropriate separation from any commercial advisory, asset-readiness, or business development activities conducted by separate commercial entities.
Governance focus points
Concise, public-interest guardrails that protect the integrity of education, research, and responsible translation.
Education & public-interest research
Programs remain mission-led, with outputs prioritized for open learning and evidence standards.
Non-confidential collaboration
Engagements focus on shared frameworks and public-interest dialogue, not proprietary deal work.
Transparent sponsorship
Funding relationships are disclosed to preserve neutrality and public trust.
Conflict disclosure
Material affiliations are acknowledged to ensure credibility across all public outputs.
Responsible evidence communication
Claims are anchored to validated data and framed with scientific caution.
No securities solicitation
The Institute does not solicit investments or participate in securities transactions.
No commercial project endorsement
Participation does not imply endorsement, diligence, or commercial validation of any project.
Contact
An institutional channel for focused, evidence-first collaboration.
We welcome serious inquiries from founders, researchers, clinicians, educators, and partners advancing responsible translational oncology.
Response cadence
Considered responses within 2–3 working days.
Engagement scope
Education, evidence standards, and translational insight.
FAQ
Answers grounded in evidence and responsibility
We prioritize clarity, scientific rigor, and patient-centered translation. These responses explain what the institute is and how we engage with founders, researchers, clinicians, and collaborators.